CE Outcomes, LLC, 107 Frankfurt Circle, Birmingham, Alabama 35211, USA.
Oncologist. 2010;15(6):584-92. doi: 10.1634/theoncologist.2009-0198. Epub 2010 May 23.
Over half of new cancer cases occur in patients aged > or = 65 years. Many older patients can benefit from intensive cancer therapies, yet evidence suggests that this population is undertreated.
To assess preferences and influential factors in geriatric cancer management, practicing U.S. medical oncologists completed a survey containing four detailed vignettes exploring colon, breast, lung, and prostate cancer treatment. Participants were randomly assigned one of two surveys with vignettes that were identical except for patient age (<65 years or >70 years).
Physicians in each survey group (n = 200) were demographically similar. Intensive therapy was significantly less likely to be recommended for an older than for a younger, but otherwise identical, patient in two of the scenarios. For a woman with metastatic colon cancer (Eastern Cooperative Oncology Group [ECOG] score, 1) for whom chemotherapy was recommended, nearly all oncologists chose an intensive regimen if the patient's age was 63; but if her age was 85, one fourth of the oncologists chose a less intensive treatment. Likewise, for stage IIA breast cancer (ECOG score, 0), 93% recommended intensive adjuvant treatment for a previously healthy patient aged 63; but only 66% said they would do so if the patient's age was 75. Oncologists commonly identified patient age as an influence on treatment choice, but were even more likely to cite performance status as a determining factor.
Advanced age can deter oncologists from choosing intensive cancer therapy, even if patients are highly functional and lack comorbidities. Education on tailoring cancer treatment and a greater use of comprehensive geriatric assessment may reduce cancer undertreatment in the geriatric population.
超过一半的新发癌症病例发生在年龄≥65 岁的患者中。许多老年患者可以从强化癌症治疗中获益,但有证据表明,这一人群的治疗不足。
为了评估老年癌症管理中的偏好和影响因素,美国的肿瘤学医生完成了一项包含四个详细病例的调查,这些病例分别探讨了结肠癌、乳腺癌、肺癌和前列腺癌的治疗。参与者被随机分配到两个调查小组之一,其中一个小组的病例除了患者年龄(<65 岁或>70 岁)外,其余均相同。
每个调查小组(n=200)的医生在人口统计学上相似。在两种情况下,对于年龄较大但其他方面相同的患者,强化治疗的推荐率明显低于年轻患者。对于一名患有转移性结肠癌(东部肿瘤协作组[ECOG]评分 1 分)且建议化疗的女性患者,如果患者年龄为 63 岁,几乎所有肿瘤学家都会选择强化方案;但如果她的年龄为 85 岁,四分之一的肿瘤学家会选择不太强化的治疗方案。同样,对于 ECOG 评分为 0 的 IIA 期乳腺癌,93%的肿瘤学家建议对 63 岁健康状况良好的患者进行强化辅助治疗;但如果患者年龄为 75 岁,只有 66%的肿瘤学家会这样做。肿瘤学家通常将患者年龄视为治疗选择的影响因素,但更可能将表现状态作为决定因素。
即使患者功能良好且无合并症,年龄较大也会阻止肿瘤学家选择强化癌症治疗。针对癌症治疗的个体化和更广泛地使用综合老年评估可能会减少老年人群中的癌症治疗不足。